Neuroblastoma News and Research

Latest Neuroblastoma News and Research

Childhood cancer cells produce molecule that affects body's immune system to fight disease

Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body's immune cells, leaving them too physically drained to fight the disease, according to new research published in the journal Cancer Research today (Saturday).

3 Aug 2015

UofL conducts Phase I research study for children with relapsed tumors

Zach feels "pretty good." Sam wants to be "done with shots!" And Tyler finds it helps to "just keep thinking that at least I'm getting out of school." They are normal boys who had normal lives until cancer came into the picture. All have faced the disease for two years or more, with surgeries, chemotherapy and radiation treatments. All were diagnosed with various malignant solid tumors, went into remission and then relapsed.

17 Jul 2015

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma.

16 Jul 2015

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

US-Australian drug discovery company, Novogen Limited, today announced details of an in vivo proof of concept study that demonstrates their lead anti-tropomyosin drug candidate, Anisina, has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects.

14 Jul 2015

Researchers complete phase 1 clinical trial of new drug for children suffering from neuroblastoma

Researchers at Spectrum Health Helen DeVos Children's Hospital have completed the first clinical trial of a new treatment for children suffering from neuroblastoma. In a clinical trial led by Giselle Sholler, MD, pediatric oncologist at Helen DeVos Children's Hospital and the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), DFMO, an investigational agent, showed minimal side effects with long-term survival of three patients.

2 Jul 2015

Study may lead to better treatments for children with neuroblastoma

Researchers studying the pediatric cancer neuroblastoma have detailed how cancer-driving mutations evolve during chemotherapy, and they hope to exploit this knowledge to design better treatments for children.

30 Jun 2015

Novogen’s chemotherapy drug Anisina proves as effective anti-cancer agent in animals

US-Australian drug discovery company, Novogen Limited announced today that its candidate cytotoxic chemotherapy drug, Anisina, has proved an effective anti-cancer agent in animals, the result of which it now has been fast-tracked by the Company to come into the clinic.

24 Jun 2015

Dell extends partnership with TGen to globally expand precision medicine trial for pediatric cancer

Dell today announced its extended partnership with the Translational Genomics Research Institute to help clinical researchers and doctors globally expand the reach and impact of the world's first Food and Drug Administration-approved precision medicine trial for pediatric cancer.

11 Jun 2015

Fennec presents positive interim results from phase III trial of sodium thiosulphate at ASCO 2015

Fennec Pharmaceuticals, Inc., announced the presentation of positive interim results from a poster presented today entitled, "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)."

2 Jun 2015

Johns Hopkins scientists safely use immune cells to treat multiple myeloma

In a report on what is believed to be the first small clinical trial of its kind, researchers at the Johns Hopkins Kimmel Cancer Center say they have safely used immune cells grown from patients' own bone marrow to treat multiple myeloma, a cancer of white blood cells.

21 May 2015

Researchers make major step toward finding target to combat drug-resistant neuroblastoma

Researchers at Children's Hospital Los Angeles have made an important step toward finding a target in the fight against drug-resistant neuroblastoma (NBL), the most common solid malignancy found, outside of the skull, in children.

14 May 2015

UM cell biologist advances research about behavior of cell proteins in neuroblastoma

Patience and persistence are beginning to pay off for University of Montana Professor Mark Grimes, whose research about the behavior of cell proteins in childhood cancer recently was published by the Public Library of Science Computational Biology.

From Cell Signaling Technology 10 May 2015

UQDI reveals that Anisina drug can kill melanoma cells

US-Australian drug discovery company, Novogen, today announced that studies conducted at The University of Queensland Diamantina Institute revealed that experimental drug, Anisina, killed melanoma cells irrespective of their mutational status.

9 Apr 2015

MabVax closes $11.6 million in private placement

MabVax Therapeutics Holdings, Inc., a clinical-stage cancer immunotherapy company, is pleased to announce that it has closed on gross proceeds of approximately $11.6 million in a private placement (the "Private Placement") led by OPKO Health, Inc. and Dr. Phillip Frost, CEO and Chairman of OPKO Health.

6 Apr 2015

Nanoparticle technique inhibits tumor growth, prolongs survival in animal models

Delving into the world of the extremely small, researchers are exploring how biodegradable nanoparticles can precisely deliver anticancer drugs to attack neuroblastoma, an often-deadly children's cancer.

3 Apr 2015

Novogen appoints PCG Advisory to manage investor-awareness program in the US

Novogen Ltd today announced it has appointed US-based public relations firm, PCG Advisory (PCG), to drive the Company's investor-awareness program in the US. PCG will be using their expertise in creating awareness and establishing key relationships within the US investment community via their targeted outreach campaign.

2 Apr 2015

Researchers identify new role for VEGFA that may help target metastatic neuroblastoma

Healthy bone is continuously involved in a dynamic process that includes bone deposition and bone resorption.

23 Mar 2015

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

10 Mar 2015

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Novogen today announces that Professor Gil Mor MD PhD from Yale Medical School will be presenting pre-clinical data on the lead candidate product, Cantrixil, at two upcoming conferences.

6 Mar 2015

Novogen's TRXE-009 therapy shows promise against brain cancer

Australian/US biotechnology company, Novogen Limited, today announces that it has confirmed that one of its lead candidate products, TRXE-009, is showing the potential to become an important new therapy in the fight against adult and pediatric brain cancer.

4 Mar 2015

Neuroblastoma News and Research

Latest Neuroblastoma News and Research

Childhood cancer cells produce molecule that affects body's immune system to fight disease

UofL conducts Phase I research study for children with relapsed tumors

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

Researchers complete phase 1 clinical trial of new drug for children suffering from neuroblastoma

Study may lead to better treatments for children with neuroblastoma

Novogen’s chemotherapy drug Anisina proves as effective anti-cancer agent in animals

Dell extends partnership with TGen to globally expand precision medicine trial for pediatric cancer

Fennec presents positive interim results from phase III trial of sodium thiosulphate at ASCO 2015

Johns Hopkins scientists safely use immune cells to treat multiple myeloma

Researchers make major step toward finding target to combat drug-resistant neuroblastoma

UM cell biologist advances research about behavior of cell proteins in neuroblastoma

UQDI reveals that Anisina drug can kill melanoma cells

MabVax closes $11.6 million in private placement

Nanoparticle technique inhibits tumor growth, prolongs survival in animal models

Novogen appoints PCG Advisory to manage investor-awareness program in the US

Researchers identify new role for VEGFA that may help target metastatic neuroblastoma

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Novogen's TRXE-009 therapy shows promise against brain cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Neuroblastoma News and Research

Latest Neuroblastoma News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in